---
title: "Heron Therapeutics extends Hercules loan maturity to as late as September 1"
url: "https://aibio.space/news/heron-therapeutics-extends-hercules-loan-maturity-late-september-1/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-02-20"
section: "Debt Financing"
tickers: "NASDAQ:HRTX"
source: "https://www.sec.gov/Archives/edgar/data/818033/000095017025023958/hrtx-20250213.htm"
summary: "The later date applies only if none of the company's 1.5% convertible notes due May 24, 2026 remain outstanding. Otherwise the loan comes due earlier."
---

By the aibio.space news desk.

Sources

- [Heron Therapeutics, Inc. 8-K (2025-02-20)](https://www.sec.gov/Archives/edgar/data/818033/000095017025023958/hrtx-20250213.htm)

[HRTX](https://aibio.space/companies/heron-therapeutics/)

2025-02-20

# Heron Therapeutics extends Hercules loan maturity to as late as September 1, 2027

Tickers [HRTX](https://aibio.space/companies/heron-therapeutics/)

The later date applies only if none of the company's 1.5% convertible notes due May 24, 2026 remain outstanding. Otherwise the loan comes due earlier.

## Key facts

- **Company**: Heron Therapeutics, Inc. (NASDAQ: HRTX)

- **News type**: Debt Financing

- **Primary source**: [Heron Therapeutics, Inc. 8-K (2025-02-20)](https://www.sec.gov/Archives/edgar/data/818033/000095017025023958/hrtx-20250213.htm)

*A distant skyline over open water. Photo: Matt Bango, CC0, via StockSnap. The picture shows the field, not the companies named.*

Heron Therapeutics, Inc. has amended its Working Capital Facility Agreement with Hercules Capital, Inc. to push back the loan's maturity date, the company said in a filing dated February 20, 2025.

The first amendment, signed on February 13, 2025, sets the maturity as the earlier of September 1, 2027 or a date tied to the company's 1.5% Convertible Senior Notes due May 24, 2026. Convertible notes are debt that the holder can turn into shares.

If any of those notes are still outstanding, the loan instead comes due on May 12, 2026. If the maturity of the notes is extended before May 12, 2026 to August 11, 2026 or later, the loan comes due ninety-one days before the extended note maturity date.

The original loan agreement is dated August 9, 2023. Hercules Capital acts as administrative agent and collateral agent for the lenders.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

HRTX

Heron Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/heron-therapeutics-extends-hercules-loan-maturity-late-september-1/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Heron Therapeutics extends Hercules loan maturity to as late as September 1", 2025-02-20, https://aibio.space/news/heron-therapeutics-extends-hercules-loan-maturity-late-september-1/